[Secondary prevention after acute coronary syndrome--role of modern drug therapy]

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Context:

• Acute coronary syndrome (ACS) management is evolving, yet early complication rates persist.
• Current guidelines recommend Aspirin as standard antithrombotic therapy.
• High-risk ACS patients not undergoing invasive procedures benefit from dual antiplatelet therapy with Aspirin and Clopidogrel.

Purpose:

• To outline current best practices for managing acute coronary syndrome.
• To emphasize early interventions and risk stratification.
• To highlight the role of specific pharmacotherapies in reducing cardiovascular risk.

Summary:

• Standard treatment includes Aspirin 100 mg/d; high-risk patients receive Aspirin plus Clopidogrel if not undergoing invasive procedures.
• Statins are crucial in the early phase of ACS, irrespective of cholesterol levels, with dose adjustments recommended at three months.
• ACE inhibitors are recommended for diabetic patients to reduce cardiovascular risk, even without hypertension or heart failure. Risk stratification requires reassessment six months post-event.

Impact:

• Optimized early management of ACS can reduce complication rates.
• Personalized pharmacotherapy, including dual antiplatelet therapy and statins, improves patient outcomes.
• Integration of ACE inhibitors and regular risk stratification enhances long-term cardiovascular health for ACS survivors, particularly those with diabetes.